Considering that co-inhibitory molecules have been explored to promote anticancer T-cell responses and constitute therapeutic targets in the treatment of melanoma (25), we decided to assess the transcriptional levels of TIM-3 and LAG-3 in PBMCS exposed to iSec. This evidence concerns the gene LAG3 and melanoma.